These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 10051059)

  • 1. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication.
    Olesen OV; Linnet K
    Ther Drug Monit; 1999 Feb; 21(1):87-90. PubMed ID: 10051059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication.
    Linnet K; Olesen OV
    Ther Drug Monit; 2002 Aug; 24(4):512-7. PubMed ID: 12142636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quetiapine serum concentrations in psychiatric patients: the influence of comedication.
    Hasselstrøm J; Linnet K
    Ther Drug Monit; 2004 Oct; 26(5):486-91. PubMed ID: 15385830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Monitoring of serum olanzapine during antipsychotic treatment].
    Linnet K; Olesen OV
    Ugeskr Laeger; 2000 Sep; 162(36):4802-5. PubMed ID: 10994377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting.
    Skogh E; Reis M; Dahl ML; Lundmark J; Bengtsson F
    Ther Drug Monit; 2002 Aug; 24(4):518-26. PubMed ID: 12142637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine.
    Carrillo JA; Herráiz AG; Ramos SI; Gervasini G; Vizcaíno S; Benítez J
    J Clin Psychopharmacol; 2003 Apr; 23(2):119-27. PubMed ID: 12640212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication.
    Theisen FM; Haberhausen M; Schulz E; Fleischhaker C; Clement HW; Heinzel-Gutenbrunner M; Remschmidt H
    Ther Drug Monit; 2006 Dec; 28(6):750-9. PubMed ID: 17164690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers.
    Penzak SR; Hon YY; Lawhorn WD; Shirley KL; Spratlin V; Jann MW
    J Clin Psychopharmacol; 2002 Aug; 22(4):366-70. PubMed ID: 12172335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication.
    Gex-Fabry M; Balant-Gorgia AE; Balant LP
    Ther Drug Monit; 2003 Feb; 25(1):46-53. PubMed ID: 12548144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism.
    Lucas RA; Gilfillan DJ; Bergstrom RF
    Eur J Clin Pharmacol; 1998 Oct; 54(8):639-43. PubMed ID: 9860152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring].
    Rao ML; Hiemke C; Grasmäder K; Baumann P;
    Fortschr Neurol Psychiatr; 2001 Nov; 69(11):510-7. PubMed ID: 11704898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes.
    Hägg S; Spigset O; Lakso HA; Dahlqvist R
    Eur J Clin Pharmacol; 2001 Sep; 57(6-7):493-7. PubMed ID: 11699614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interindividual variation in olanzapine concentration influenced by UGT1A4 L48V polymorphism in serum and upstream FMO polymorphisms in cerebrospinal fluid.
    Mao M; Skogh E; Scordo MG; Dahl ML
    J Clin Psychopharmacol; 2012 Apr; 32(2):287-9. PubMed ID: 22388157
    [No Abstract]   [Full Text] [Related]  

  • 14. D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study.
    Meisenzahl EM; Dresel S; Frodl T; Schmitt GJ; Preuss UW; Rossmüller B; Tatsch K; Mager T; Hahn K; Möller HJ
    J Psychopharmacol; 2000; 14(4):364-70. PubMed ID: 11198054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentration.
    Markowitz JS; DeVane CL
    J Clin Psychopharmacol; 1999 Jun; 19(3):289-91. PubMed ID: 10350045
    [No Abstract]   [Full Text] [Related]  

  • 16. Olanzapine serum concentrations lowered by concomitant treatment with carbamazepine.
    Licht RW; Olesen OV; Friis P; Laustsen T
    J Clin Psychopharmacol; 2000 Feb; 20(1):110-2. PubMed ID: 10653223
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service.
    Castberg I; Spigset O
    Pharmacopsychiatry; 2007 May; 40(3):107-10. PubMed ID: 17541885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men.
    Macias WL; Bergstrom RF; Cerimele BJ; Kassahun K; Tatum DE; Callaghan JT
    Pharmacotherapy; 1998; 18(6):1237-48. PubMed ID: 9855322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-performance liquid chromatography with electrochemical detection.
    Aravagiri M; Ames D; Wirshing WC; Marder SR
    Ther Drug Monit; 1997 Jun; 19(3):307-13. PubMed ID: 9200772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine excretion in human breast milk: estimation of infant exposure.
    Croke S; Buist A; Hackett LP; Ilett KF; Norman TR; Burrows GD
    Int J Neuropsychopharmacol; 2002 Sep; 5(3):243-7. PubMed ID: 12366877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.